13 November 2026 in European Heart Journal Open
Aims: Oxygen uptake at the first ventilatory threshold (VT1) can be expressed as an absolute value (VO2VT1-abs), as a percentage of predicted peak VO2 (VO2VT1-%pred), or as a percentage of observed peak VO2 (VO2VT1-%obs). We compared their prognostic performance in transthyretin cardiac amyloidosis (ATTR-CM). Methods and Results: Adults with ATTR-CM undergoing baseline cardiopulmonary exercise testing at two centres were studied. Endpoints were all-cause mortality and death or heart failure (HF) hospitalisation. Censoring-aware 2-year discrimination and age- and sex-adjusted Cox associations were assessed. Incremental model fit and discrimination beyond age, sex, peak VO2, and VE/VCO2 slope were evaluated, with bootstrap internal validation. Among 182 patients, VT1 was identifiable in 173 (95.1%). Mortality follow-up was available in 162 patients (44 deaths), and composite follow-up in 157 (66 events). Per 1-standard-deviation decrease, VO2VT1-abs and VO2VT1-%pred were associated with mortality (hazard ratio [HR] 2.86, 95% confidence interval [CI] 1.77–4.63; and HR 2.50, 95% CI 1.61–3.87; both P<0.001) and the composite endpoint (HR 2.25, 95% CI 1.53–3.31; and HR 2.38, 95% CI 1.65–3.43; both P<0.001). VO2VT1-%obs was not associated with either endpoint. Adding VO2VT1-abs or VO2VT1-%pred improved mortality model fit (likelihood-ratio P=0.019 and P=0.034), but bootstrap 95% CIs for both gains in C-index included zero. Severe-limitation analyses were exploratory, without significant interactions. Conclusion: Absolute and predicted-normalised VT1 were associated with outcomes; non-proportional hazards warrant caution for absolute-VT1 mortality. Improved model fit does not establish improved predictive discrimination, clinical utility, or added value beyond comprehensive ATTR-CM risk stratification. External validation is required.
23 July 2026 in European Journal of Preventive Cardiology
Aims: To evaluate the applicability of the RoMa classification in patients with transthyretin cardiac amyloidosis (ATTR-CM) and to assess its association with functional capacity and key cardiopulmonary exercise testing (CPET) parameters. Methods and results: Consecutive adults (≥18 years) with confirmed ATTR-CM from two tertiary centres who completed symptom-limited maximal CPET were included. RoMa classes were defined using predefined cut-offs for per cent-predicted peak heart rate (HRpp ≥80%) and per cent-predicted peak O2-pulse (O2pp ≥100%): RoMa I (high HRpp/high O2pp), RoMa II (high HRpp/low O2pp), RoMa III (low HRpp/high O2pp), and RoMa IV (low HRpp/low O2pp). We evaluated 165 patients (90% male; 77% wild-type ATTR, 20% variant ATTR). RoMa distribution was as follows: RoMa I, n = 33; RoMa II, n = 73; RoMa III, n = 30; and RoMa IV, n = 29. Age did not differ across classes (P = 0.36). Functional capacity declined across the RoMa strata: median 6-min walk distance (6MWD) decreased from 420 (RoMa I) to 313 m (RoMa IV) (overall P = 0.009; P-trend = 0.005), and NYHA class worsened (overall P = 0.003; P-trend = 0.005). Peak VO2 (% predicted) differed between groups (RoMa I: 93.0; II: 70.8; III: 75.2; IV: 51.9; overall P < 0.001; P-trend < 0.001), and ventilatory inefficiency increased (VE/VCO2 slope: 34; 39; 37; 47, respectively; overall P < 0.001; P-trend < 0.001; peak PetCO2: 30; 27; 29; 25, respectively; overall P < 0.001; P-trend = 0.003). 6MWD correlated with peak VO2 (r = 0.626; P < 0.001; n = 131) and inversely with VE/VCO2 slope (ρ = −0.484; P < 0.001; n = 130). Conclusion: In ATTR-CM, application of the RoMa classification was feasible and identified distinct CPET-derived exercise-response profiles associated with functional impairment. These findings support RoMa as a promising exploratory framework for functional phenotyping in ATTR-CM.
22 October 2026 in European Heart Journal Open
Aims: To assess the association of 1-min heart rate recovery (HRR1) with clinical outcomes and its incremental contribution to model fit beyond peak VO2 and ventilatory efficiency (VE/VCO2 slope) in transthyretin cardiac amyloidosis (ATTR-CM). Methods and results: Consecutive adults with confirmed ATTR-CM undergoing symptom-limited cardiopulmonary exercise testing (CPET) were included in this single-centre observational study. During standardized active recovery at 24 W, HRR1 was defined as peak heart rate minus heart rate exactly 60 s after exercise. Cox proportional-hazards models evaluated all-cause mortality and the composite of mortality or first heart-failure hospitalization. Principal models adjusted for age, sex, peak VO2 and VE/VCO2 slope; NT-proBNP and National Amyloidosis Centre (NAC) stage were examined separately. Of 161 baseline patients, 11 with unverifiable heart-rate measurements were excluded, and exact HRR1 was available in 110. Mortality analysis included 105 patients with 33 deaths; composite-outcome analysis included 107 patients with 51 events. Median HRR1 was 15.5 bpm. In conventional CPET-adjusted models, each 10-bpm greater HRR1 was associated with lower hazards of mortality [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.44–0.95; P = 0.028] and the composite outcome (HR 0.74, 95% CI 0.57–0.97; P = 0.029). Adding HRR1 improved model fit (likelihood-ratio P = 0.017 and P = 0.021, respectively); apparent C-indices increased from 0.770 to 0.795 for mortality and from 0.695 to 0.699 for the composite outcome. Associations were non-significant after separate adjustment for NT-proBNP or NAC stage. Conclusion: HRR1 remained associated with outcomes after CPET adjustment and improved model fit. Discrimination gains were modest; value beyond biomarker staging was unproven.